Does weight loss slow down on Mounjaro, and is that normal?

The biggest myth: a slower week means Mounjaro is wearing off

It doesn't. This is a question our prescribers hear most weeks, and the reassurance is almost always the same: a week or two of slower movement on the scales is not evidence that tirzepatide has lost its effect. What's happening is more straightforward than that.

When you lose weight, your body needs fewer calories to keep itself running. A smaller body burns less energy at rest. At the same time, hormones that regulate hunger (particularly leptin) shift in ways that can increase appetite signals over time. These are protective biological mechanisms, not a flaw in your treatment. Mounjaro works by activating both GIP and GLP-1 receptors, reducing appetite and slowing the passage of food through the stomach. That action is genuine and measurable. But it operates within a body that is also adapting, and adaptation takes time to show up clearly on a scale.

The tirzepatide overview covers the mechanism in detail if you want the fuller picture. For now, the key point is this: a temporary slowdown is not the same as a plateau, and neither is the same as Mounjaro stopping work. The distinction matters because each calls for a different response.

What a real plateau on Mounjaro looks like, and why it happens

A true plateau is usually defined as four to six weeks or more of stable weight despite no significant change in diet, activity or sleep. At that point it is worth thinking about a few things.

First, dose. Tirzepatide is titrated from 2.5 mg upward through six licensed strengths. The starting dose exists to let the body adjust to the medicine; the therapeutic effect on appetite builds as the dose increases. If you are still at a lower dose, a prescriber-led increase may shift appetite suppression enough to restart progress. The guidance on what to do when weight loss has slowed goes into the practical steps in more detail.

Second, energy intake and protein. It is surprisingly common for food intake to drift upward subtly over time, especially as nausea from early doses fades and meals become more comfortable again. Adequate protein and fibre help maintain fullness between doses. The NHS's resources on healthy weight management are a useful starting point for thinking about diet alongside treatment.

Third, activity. Muscle mass tends to fall alongside fat during significant weight loss. Strength-based activity (even gentle resistance work) helps preserve metabolic rate. This doesn't have to mean a gym; it means not treating rest as the only tool available.

Fourth, sleep and stress. Both affect the hormones that govern hunger. Poor sleep reliably increases ghrelin (a hunger hormone) and can blunt the satiety effect of GLP-1 medicines. Worth ruling out before assuming the medicine is at fault.

What the trial data tells us about the shape of weight loss on tirzepatide

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants losing weight on tirzepatide did not lose it at a flat, constant rate across 72 weeks. The curve is steepest in the first few months and then flattens as weight approaches a new equilibrium. Average losses of around 20–21% of body weight at the 15 mg dose were recorded, but these figures represent the end of over a year of treatment, not a steady weekly line. SURMOUNT-1 in the NEJM gives the detail for anyone who wants to read the primary evidence.

This shape (fast early, then gradually levelling) is consistent with what happens in any sustained calorie deficit. The body is not broken; it is doing exactly what bodies do. If you have noticed that your weight loss is slowing down on Mounjaro, it helps to understand which of these factors, dose, diet, sleep or stress, is most likely driving the change. Those are the levers, and a prescriber can help you work out which ones need adjusting. If you are wondering specifically why your loss has become slow at your current dose, that page covers the dose-specific picture.

When to raise it with a prescriber, and what to expect

If your loss has been static for more than a month, it's reasonable to flag this. Not because something is necessarily wrong, but because a prescriber can look at the whole picture: your current dose, how long you've been on it, your side-effect history, whether you're near a planned titration point, and whether lifestyle factors might be playing a bigger role than the medicine alone can address.

For context on what tirzepatide costs privately, the weight-loss treatments overview sets out how pricing works and what a clinically supervised plan includes. Dose increases, where clinically suitable, require a prescriber's sign-off, at nume this happens as part of the repeat-order review process, not as a separate paid consultation.

Mounjaro is a prescription-only medicine for a reason. Our guidance on Mounjaro slow weight loss is worth reading if you want a fuller picture of why progress can feel uneven and what options are available to you. If you want to speak to someone about whether your current plan is still the right one, speaking to our prescribers is the practical next step, no waiting list, reviewed the same working day. Start a free consultation here.